Home › Funds › Prosight Management, LP › DNLI
Prosight Management, LP position in DNLI
DENALI THERAPEUTICS INC · Health Care
Prosight Management, LP reported holding 550,700 shares of DNLI (DENALI THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$11.4M, representing 2.21% of its reported portfolio and ranking #15 among its reported holdings. Prosight Management, LP first reported this position in Q3 2026.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Prosight Management, LP's DNLI position evolved
Prosight Management, LP first disclosed a stake in DNLI in Q3 2026 at 550,700 shares (US$11.4M).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2026 | 550.70K | $11.38M | New |
About DNLI and 13F data
DNLI (DENALI THERAPEUTICS INC) is a Health Care company. 39 other funds we track also report a position in DNLI — the largest reported positions include Temasek Holdings (US$180.4M), Temasek Holdings (Private) Ltd (US$145.0M), BAKER BROS. ADVISORS LP (US$96.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding DNLI
- Temasek Holdings 7.01M sh · $180.37M · Q2 2026
- Temasek Holdings (Private) Ltd 7.01M sh · $144.96M · Q3 2026
- BAKER BROS. ADVISORS LP 3.73M sh · $96.05M · Q2 2026
- Casdin Capital 2.04M sh · $52.60M · Q2 2026
- Crestline Management, L.P. 1.91M sh · $49.14M · Q2 2026
- Foresite Capital Management VI LLC 1.40M sh · $35.92M · Q2 2026
- Siren, L.L.C. 1.40M sh · $28.87M · Q3 2026
More on Prosight Management, LP
FAQ
How long has Prosight Management, LP held DNLI?
Prosight Management, LP has disclosed DNLI holdings in 1 of the last 1 reported quarters, going back to Q3 2026.
What is Prosight Management, LP's current position in DNLI?
As of Q3 2026, Prosight Management, LP holds 550.70K shares of DNLI (DENALI THERAPEUTICS INC), valued at $11.38M, representing 2.21% of its reported portfolio and ranking #15.
Has Prosight Management, LP been buying or selling DNLI?
In the latest 13F filing (Q3 2026), Prosight Management, LP newly opened its position in DNLI.
Which other funds hold DNLI?
Other major institutional holders of DNLI include Temasek Holdings, Temasek Holdings (Private) Ltd, BAKER BROS. ADVISORS LP, among 39 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.